Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Accured Expenses (2016 - 2025)

Rocket Pharmaceuticals' Change in Accured Expenses history spans 10 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 1101.94% year-over-year to $9.3 million; the TTM value through Dec 2025 reached -$81000.0, down 101.34%, while the annual FY2025 figure was -$81000.0, 101.34% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $9.3 million at Rocket Pharmaceuticals, up from -$9.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.8 million in Q4 2023 and bottomed at -$16.0 million in Q2 2021.
  • The 5-year median for Change in Accured Expenses is $1.6 million (2022), against an average of $1.3 million.
  • The largest annual shift saw Change in Accured Expenses plummeted 929.66% in 2021 before it skyrocketed 1101.94% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.8 million in 2021, then dropped by 10.8% to $2.5 million in 2022, then surged by 534.12% to $15.8 million in 2023, then tumbled by 95.09% to $774000.0 in 2024, then surged by 1101.94% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Change in Accured Expenses are $9.3 million (Q4 2025), -$9.3 million (Q3 2025), and $5.2 million (Q2 2025).